Dr. Lekakis on Current Research With CAR T-Cell Therapy

Lazaros John Lekakis, MD
Published: Friday, Mar 15, 2019



Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Bispecific CAR T cells are an area of active investigation in B-cell malignancies, explains Lekakis. Currently, tisagenlecleucel (Kymriah) and axicabtagene-ciloleucel (Yescarta) are approved for patients with relapsed or refractory diffuse large B-cell lymphoma, both of which target CD19. Some of the dual targets under investigation include CD19 and CD22. Dual-targeted CAR T cells may be more effective, explains Lekakis as CAR T-cell evasion can occur with CD19 clones, he explains.

In multiple myeloma, several products are under investigation––all of which target BCMA. Some companies are combining CAR T cells with PD-1/PD-L1 inhibitors to try to evade T-cell exhaustion, explains Lekakis. Combinations of CD19-specific CAR T cells and lenalidomide (Revlimid) and rituximab (Rituxan) are also under exploration, adds Lekakis.
SELECTED
LANGUAGE


Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Bispecific CAR T cells are an area of active investigation in B-cell malignancies, explains Lekakis. Currently, tisagenlecleucel (Kymriah) and axicabtagene-ciloleucel (Yescarta) are approved for patients with relapsed or refractory diffuse large B-cell lymphoma, both of which target CD19. Some of the dual targets under investigation include CD19 and CD22. Dual-targeted CAR T cells may be more effective, explains Lekakis as CAR T-cell evasion can occur with CD19 clones, he explains.

In multiple myeloma, several products are under investigation––all of which target BCMA. Some companies are combining CAR T cells with PD-1/PD-L1 inhibitors to try to evade T-cell exhaustion, explains Lekakis. Combinations of CD19-specific CAR T cells and lenalidomide (Revlimid) and rituximab (Rituxan) are also under exploration, adds Lekakis.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x